Cite
HARVARD Citation
Findlay, A. et al. (2021). An activity‐based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti‐fibrotic therapeutic strategies. Clinical and translational medicine. 11 (11), p. n/a. [Online].